Total Payments
$75,672
2024 Payments
$34,931
Companies
13
Transactions
93
Medicare Patients
11,801
Medicare Billing
$4.4M
Payment Breakdown by Category
Other$59,430 (78.5%)
Travel$7,275 (9.6%)
Consulting$6,510 (8.6%)
Food & Beverage$2,425 (3.2%)
Education$31.92 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $59,430 | 25 | 78.5% |
| Travel and Lodging | $7,275 | 17 | 9.6% |
| Consulting Fee | $6,510 | 3 | 8.6% |
| Food and Beverage | $2,425 | 46 | 3.2% |
| Education | $31.92 | 2 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | $62,260 | 53 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $12,810 | 16 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $143.12 | 3 | $0 (2024) |
| Kite Pharma, Inc. | $125.00 | 1 | $0 (2018) |
| Astellas Pharma US Inc | $117.97 | 9 | $0 (2019) |
| Janssen Biotech, Inc. | $59.87 | 3 | $0 (2024) |
| Myriad Genetic Laboratories, Inc. | $50.34 | 2 | $0 (2023) |
| Dendreon Pharmaceuticals LLC | $32.09 | 1 | $0 (2024) |
| Aveo Pharmaceuticals, Inc. | $20.00 | 1 | $0 (2024) |
| Heron Therapeutics, Inc. | $16.50 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $34,931 | 39 | JAZZ PHARMACEUTICALS INC. ($22,120) |
| 2023 | $33,429 | 30 | JAZZ PHARMACEUTICALS INC. ($33,378) |
| 2022 | $5,387 | 4 | JAZZ PHARMACEUTICALS INC. ($5,387) |
| 2021 | $1,387 | 4 | JAZZ PHARMACEUTICALS INC. ($1,375) |
| 2019 | $15.23 | 1 | Astellas Pharma US Inc ($15.23) |
| 2018 | $443.92 | 9 | E.R. Squibb & Sons, L.L.C. ($128.41) |
| 2017 | $78.85 | 6 | Astellas Pharma US Inc ($37.23) |
All Payment Transactions
93 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Education | In-kind items and services | $20.00 | General |
| Category: Oncology | ||||||
| 12/11/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $460.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $31.00 | General |
| Category: Oncology | ||||||
| 11/20/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $14.71 | General |
| Category: Oncology | ||||||
| 10/15/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $250.00 | General |
| Category: Oncology | ||||||
| 09/19/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $250.00 | General |
| Category: Oncology | ||||||
| 09/17/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $25.69 | General |
| Category: Oncology | ||||||
| 09/08/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $118.38 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 08/28/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $17.67 | General |
| Category: Oncology | ||||||
| 08/27/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Travel and Lodging | In-kind items and services | $362.96 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 08/13/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $32.09 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 08/07/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,140.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 07/29/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Travel and Lodging | In-kind items and services | $1,992.75 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 07/27/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $94.13 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 07/17/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $13.96 | General |
| Category: Oncology | ||||||
| 06/26/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $22.42 | General |
| 06/20/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA, BALVERSA | Food and Beverage | In-kind items and services | $16.51 | General |
| Category: Oncology | ||||||
| 06/18/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Travel and Lodging | In-kind items and services | $237.48 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 04/29/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,140.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 04/20/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $95.02 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 04/03/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,500.00 | General |
| Category: Oncology | ||||||
| 03/28/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Travel and Lodging | In-kind items and services | $140.70 | General |
| Category: Oncology | ||||||
| 03/28/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $67.59 | General |
| Category: Oncology | ||||||
| 03/27/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Travel and Lodging | In-kind items and services | $227.60 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 03/27/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Travel and Lodging | In-kind items and services | $181.98 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 52 | 2,437 | 83,801 | $2.7M | $1.0M |
| 2022 | 54 | 3,189 | 94,791 | $3.1M | $1.2M |
| 2021 | 57 | 3,035 | 96,550 | $2.8M | $1.2M |
| 2020 | 58 | 3,140 | 83,183 | $2.5M | $969,200 |
Total Patients
11,801
Total Services
358,325
Medicare Billing
$4.4M
Procedure Codes
221
All Medicare Procedures & Services
221 procedure records from CMS Medicare Utilization — Page 1 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 23 | 16,000 | $1.6M | $680,207 | 42.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 17 | 3,000 | $135,000 | $54,265 | 40.2% |
| Q5115 | Injection, rituximab-abbs, biosimilar, (truxima), 10 mg | Office | 2023 | 11 | 1,400 | $154,000 | $48,837 | 31.7% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 11 | 1,210 | $102,850 | $43,479 | 42.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 198 | 401 | $110,056 | $35,634 | 32.4% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 14 | 13,000 | $104,000 | $31,116 | 29.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 107 | 319 | $111,650 | $29,668 | 26.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 61 | 162 | $35,640 | $14,353 | 40.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 75 | 116 | $42,835 | $13,868 | 32.4% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 116 | 407 | $34,595 | $8,487 | 24.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 125 | 149 | $28,257 | $8,307 | 29.4% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 22 | 5,200 | $22,100 | $6,973 | 31.6% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 24 | 15,810 | $23,715 | $5,985 | 25.2% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 189 | 487 | $13,636 | $4,973 | 36.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 70 | 107 | $25,680 | $4,737 | 18.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 33 | 34 | $13,940 | $4,391 | 31.5% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 15 | 77 | $15,015 | $4,040 | 26.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 194 | 520 | $15,080 | $3,908 | 25.9% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 32 | 73 | $12,775 | $3,389 | 26.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 173 | 381 | $3,810 | $3,144 | 82.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 17 | 17 | $6,970 | $2,492 | 35.7% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 51 | 167 | $9,185 | $1,876 | 20.4% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 32 | 89 | $7,120 | $1,825 | 25.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 14 | 14 | $4,550 | $1,596 | 35.1% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 30 | 177 | $5,310 | $1,577 | 29.7% |
About Dr. Mathew Wehbe, MD
Dr. Mathew Wehbe, MD is a Hematology healthcare provider based in Des Moines, Iowa. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/21/2007. The National Provider Identifier (NPI) number assigned to this provider is 1619186368.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mathew Wehbe, MD has received a total of $75,672 in payments from pharmaceutical and medical device companies, with $34,931 received in 2024. These payments were reported across 93 transactions from 13 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($59,430).
As a Medicare-enrolled provider, Wehbe has provided services to 11,801 Medicare beneficiaries, totaling 358,325 services with total Medicare billing of $4.4M. Data is available for 4 years (2020–2023), covering 221 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Medical Oncology
- Location Des Moines, IA
- Active Since 05/21/2007
- Last Updated 10/01/2022
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1619186368
Products in Payments
- ZEPZELCA (Drug) $62,141
- TAGRISSO (Drug) $12,174
- IMFINZI (Biological) $431.00
- CALQUENCE (Drug) $138.96
- Yescarta (Drug) $125.00
- EMPLICITI (Biological) $122.60
- VYXEOS (Drug) $119.04
- MYRBETRIQ (Drug) $69.88
- MYRISK (Device) $50.34
- Myrbetriq (Drug) $37.23
- ERLEADA (Drug) $34.18
- PROVENGE (Drug) $32.09
- RYBREVANT (Drug) $25.69
- OPDIVO (Biological) $20.52
- FOTIVDA (Drug) $20.00
- SUSTOL (Drug) $16.50
- Avastin (Biological) $12.81
- TAXOTERE (Drug) $12.31
- VESICARE (Drug) $10.86
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.